Delivery Order SPE2DB20D2104-SPE2DB25FMSQW

Award Date 6/5/25
Potential Completion Date 6/6/25
Potential Value $5.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order worth $11,191.84 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of May 22, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $6,084.95 firm fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a period of performance through December 20, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,798.90 firm fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award has an ultimate completion date of February 2, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,208.56 firm fixed-price delivery order contract covers the supply of XIFAXAN 550 MG TABLET 60S, a prescription medication, with a period of performance through January 8, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,721.40, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The $19,179.94 firm fixed-price delivery order has an ultimate completion date of December 31, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,315.91 firm fixed-price delivery order is for the supply of XIFAXAN 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary mechanism for the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,497.29 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a specialty pharmaceutical product. The contract has an ultimate completion date of May 5, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award to Amerisourcebergen Drug Corp is a delivery order with a firm fixed price of $1,213.74 and a completion date of June 3, 2024. The contract was awarded by the Defense Logistics Agency (DLA) for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a comprehensive vehicle for...
This federal contract award, valued at $11,806.49, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2025 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMSQW
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,397.03 firm-fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has a period of performance through June 6, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers such as the Defense Health Agency and U.S. Coast Guard. The contract award does not indicate a set-aside designation, suggesting it was competed on an unrestricted basis.

Generated 9/4/25, 9:45 AM